Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Buy Rating at SunTrust Banks, Inc.

SunTrust Banks, Inc. reiterated their buy rating on shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in a report issued on Thursday morning.

SRPT has been the topic of a number of other research reports. Cowen and Company restated a buy rating on shares of Sarepta Therapeutics in a research note on Friday, April 28th. Robert W. Baird restated an outperform rating and issued a $102.00 target price on shares of Sarepta Therapeutics in a research note on Sunday, April 23rd. Leerink Swann restated an outperform rating and issued a $52.00 target price (up previously from $47.00) on shares of Sarepta Therapeutics in a research note on Saturday, April 29th. Piper Jaffray Companies set a $43.00 target price on Sarepta Therapeutics and gave the stock a buy rating in a research note on Thursday, May 18th. Finally, Vetr downgraded Sarepta Therapeutics from a strong-buy rating to a buy rating and set a $37.67 target price on the stock. in a research note on Monday, April 24th. Seven equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Sarepta Therapeutics has an average rating of Buy and a consensus price target of $60.90.

Shares of Sarepta Therapeutics (NASDAQ SRPT) traded up 6.06% on Thursday, reaching $43.41. The company had a trading volume of 7,594,038 shares. The stock has a 50-day moving average price of $33.69 and a 200-day moving average price of $32.07. Sarepta Therapeutics has a 12 month low of $22.61 and a 12 month high of $63.73. The stock’s market cap is $2.39 billion.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Wednesday, July 19th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.46. The company had revenue of $35.01 million for the quarter, compared to analyst estimates of $22.52 million. Sarepta Therapeutics’s revenue for the quarter was up 350000.0% on a year-over-year basis. During the same quarter last year, the firm posted ($1.19) EPS. Analysts predict that Sarepta Therapeutics will post ($0.78) earnings per share for the current fiscal year.

WARNING: This story was originally posted by [[site]] and is the property of of [[site]]. If you are reading this story on another site, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at [[permalink]].

A number of large investors have recently modified their holdings of SRPT. Russell Investments Group Ltd. boosted its stake in shares of Sarepta Therapeutics by 63.9% in the first quarter. Russell Investments Group Ltd. now owns 38,273 shares of the biotechnology company’s stock worth $1,133,000 after buying an additional 14,919 shares during the last quarter. Sigma Planning Corp boosted its stake in shares of Sarepta Therapeutics by 7.8% in the first quarter. Sigma Planning Corp now owns 12,895 shares of the biotechnology company’s stock worth $382,000 after buying an additional 930 shares during the last quarter. Columbus Circle Investors boosted its stake in shares of Sarepta Therapeutics by 175.0% in the first quarter. Columbus Circle Investors now owns 34,027 shares of the biotechnology company’s stock worth $1,007,000 after buying an additional 21,652 shares during the last quarter. Fox Run Management L.L.C. acquired a new stake in shares of Sarepta Therapeutics during the first quarter worth about $388,000. Finally, Bank of Montreal Can boosted its position in Sarepta Therapeutics by 1.0% in the first quarter. Bank of Montreal Can now owns 98,775 shares of the biotechnology company’s stock valued at $2,924,000 after buying an additional 996 shares during the last quarter. 73.13% of the stock is currently owned by institutional investors and hedge funds.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).